The values were interpreted as follows: DLCO and DLCOHb: Normal (>80% predicted) Mild diffusion defect (65-80%), Moderate diffusion defect (45-65%) and severe diffusion defect (<45%).
There were 3 patients with restrictive ventilatory defect and no diffusion defect and 2 patients with diffusion defect and no restrictive ventilatory defect.
CUMULATIVE DOSE VS PFT: Diffusion defect and restrictive ventilatory defect occurred with least cumulative dose of 150mgs.
There were 5 patients with symptoms, no pulmonary fibrosis and diffusion defect.
Symptoms Vs Diffusion Defect Diffusion defect Normal diffusion Total Symptoms > 1 month 5 3 8 Symptoms < 1month 5 17 22 Total 10 20 30
2) patients had diffusion defect and 2 patients had restrictive pattern in spirometry.
There were 10 (33%) patients with diffusion defect in this study.
There were 7(23%) patients with diffusion defect in this study without radiological evidence of methotrexate induced pulmonary fibrosis.
3%) patients with diffusion defects without radiological abnormalities.
The reasons for the hypoxia were universally chalked up to the usual suspects which were either chronic obstructive pulmonary disease, a diffusion defect
or some vague notion that there was a sleep related hypoventilation syndrome.